DNA damage checkpoint kinases in cancer | Expert Reviews in Molecular Medicine | Cambridge Core
AZD-7762 | Chk Inhibitor | MedChemExpress
AZD7762 | ≥99%(HPLC) | Selleck | Chk inhibitor
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. | Semantic Scholar
Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide ( AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas | Journal of Medicinal Chemistry
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. - Abstract - Europe PMC
Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling
AZD7762 | ≥99%(HPLC) | Selleck | Chk inhibitor
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours | SpringerLink
The Chk1/2 inhibitor AZD7762 sensitizes SW480 colon cancer cells to... | Download Scientific Diagram
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells | Anticancer Research
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours | SpringerLink
Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro - Wang - 2018 - Cancer Medicine - Wiley Online Library
Cells | Free Full-Text | DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives | HTML
Phase I Dose-escalation Study Of AZD7762, A Checkpoint Kinase Inhibitor, In Combination With Gemcitabine In Patients With Advanced Solid Tumors. | ApconiX
Prexasertib - an overview | ScienceDirect Topics
Frontiers | Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives | Oncology
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy | Cell Death & Differentiation
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine | Journal of Experimental & Clinical Cancer Research | Full Text
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. - Abstract - Europe PMC
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine | Journal of Experimental & Clinical Cancer Research | Full Text
CHK1 inhibitor AZD7762 alone caused more cytotoxicity to RBCC but... | Download Scientific Diagram
Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine | Journal of Experimental & Clinical Cancer Research | Full Text
Effect of AR Knockdown and Chk1/2 Inhibitor AZD7762 on TopBP1-ATR-Chk1... | Download Scientific Diagram
AZD-7762
Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer | Oncogene
![PDF] AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/011855db2f855b51c20127a128a5a6952fb98545/6-Figure3-1.png "PDF] AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies | Semantic Scholar")
PDF] AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies | Semantic Scholar
